Predictive role of serum procollagen III peptide and Knodell's index in survival prognosis of patients with hepatitis B virus liver cirrhosis

Wiener Klinische Wochenschrift

Volumn 115, Issue 9, 2003, Pages 302-308

  Babić, Žarko ^a,c   Bilić, Ante ^a   Babić, Dobroslav ^a   Jagić, Vjekoslav ^b   Nikolić, Branko ^a   Sunić, Martina ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c NONE   (Croatia)

Author keywords

HBV; Knodell's index; Procollagen; Survival prognosis

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; BIOCHEMICAL MARKER; HEPATITIS B(E) ANTIBODY; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; VIRUS DNA;

ADULT; AGED; ARTICLE; ASCITES; CANONICAL ANALYSIS; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISCRIMINANT ANALYSIS; FEMALE; FIBROGENESIS; HEPATITIS B VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; KNODELL INDEX; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; PROGNOSIS; PROTHROMBIN TIME; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 0037526735     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03040336     Document Type: Article

References (33)

1. Annoni G, Colombo M, Cantalupi CM, Khalt B, Lampetrico P, Rojklind M (1989) Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic abusers. Hepatology 5: 693-697
2. Chang TT, Lin HC, Lee SD, Tsai YT, Lee FY, Jeng FS, Wu JC, Yeh PS, Lo KJ (1989) Clinical significance of serum type III procollagen amylopeptide in hepatitis B virus related diseases. Scand J Gastroenterol 24: 533-538
3. McCullough AJ, Stasen WN, Wiesner RH, Czaja AJ (1987) Serum type III procollagen peptide concentrations in severe chronic active hepatitis: relationship to cirrhosis and disease activity. Hepatology 7: 49-54
4. Murawaki Y, Ikuta Y, Nishimura Y, Koda M, Kawasaki H (1996) Serum marker for fibrosis and plasma transforming growth factor beta 1 in patients with hepatocellular carcinoma in comparison with patients with liver cirrhosis. J Gastroenterol Hepatol 11: 443-450
5. Realdi G, Fatovich G, Hadziyannis S, Hadzyannis S, Schalm SW, Almasio P, et al (1994) Survival and prognostic factors in 366 patients with compensated cirrhosis type B: multicenter study. The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 21: 656-666
6. Teare JP, Sherman D, Greenfeld SM, Simpson J, Bray G, Cattarall AP, et al (1993) Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 342: 859-868
7. Trinchet JC, Hartmann DJ, Pateron D, Laarif M, Callard P, Ville G, et al (1991) Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationshiop to liver histology and conventional liver tests. J Hepatol 2: 139-144
8. Camps J, Crisostomo S, Granero GM, Gracia-Granero M, Riezu-Boj JI, Civeira MP (1993) Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 34: 1714-1717
9. Sarin SK, Sundaram KR, Ahuja RK, Anand BS, Broor SL (1988) Young vs. adult cirrhotics: a prospective, comparative analysis of the clinical profile, natural course and survival. Gut 1: 101-107
10. Sherlock S (1997) Diseases of the liver and biliary system, 10th edn. In: Sherlock S (ed) Blackwell, Oxford London Edinburgh Boston Melbourne
11. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1: 431-435
12. Jongh FE, Jansen HL, de Man RA (1992) Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103: 1630-1635
13. Christiansen E, Schiliching P, Fauerholdt L (1984) Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 3: 430-435
14. Christiansen E, Shcilding P, Andersen KP, Fauerholdt L, Schou G, Pedersen VB, Juhl E, Poulsen H, Tygstrup N, Copenhagen Study Group for Liver Diseases (1986) Copenhagen Study Group for Liver Disease. Updating prognosis and therapeutic effects evaluation in cirrhosis with Cox's multiple regression model for time-dependent variable. Scand J Gastroenterol 21: 163-174
15. Orego H, Israeli Y, Blake JE, Medline A (1983) Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 6: 896-905
16. Behringwerke AG (1991) RIA-gnost Procollagen-III-peptide Kit for the radioimmunoassay of the procollagen III peptide. Instructions for use. Prod. No. ODMT. Behringwerke AG Diagnostica, Marburg, pp 1-27
17. Hayes P, Gimson, David W (1988) Aids to gastroenterology and hepatology. Churchill Livingstone, Edinburgh London Melbourne New York, pp 155-158
18. Niemela O, Risteli J, Blake JE, Risteli L, Compton KV, Orego (1990) Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis and alcohol intake. Gastroenterology 98: 1612-1619
19. Yamada M, Fukuda Y, Koyama Y, Nakano I, Urano F, Katano Y, Hayakawa T, et al (1996) Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol 11: 646-651
20. Neveau S, Poynard T, Abela A, Pignon JP, Poitriane A, Agostini H, Zourabichvili O, Chaput JC (1985) Prognostic value of serum fibronectin concentrations in alcoholic cirrhotic patients. Hepatology 5: 819-823
21. Bayerdörffer E, Lamerz R, Fliege R, Köpcke W, Mannes G (1991) Predictive value of serum procollagen III peptide for the survival of patients with cirrhosis. J Hepatol 13: 298-304
22. Ikeda K, Kumada H (1994) Long-term prognosis of liver cirrhosis. Nippon Rinsho 51: 63-68
23. Chu CM (2000) Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurence of cirrhosis and hepatocelullar carcinoma. J Gastroenterol Hepatol 15 [Suppl]: E25-30
24. Franklin MK, Thomas L, Fabry MP, Schafner F (1992) Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model of a group of patients with known endpoint. Gastroenterology 102: 310-313
25. Schneider JF, Baker AL, Haines NW, Baker A, Haines NW, Hatfield G, et al (1980) Aminopyrine N-determination: a prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology 79: 1145-1150
26. Siciliano M, Milani A, Marra L, Rossi L (1987) Serum bile acids in liver cirrhosis: prognostic significance evidenced by multivariate statistics model. Gastroenterology 5: 721-725
27. Fattovich G, Giustina G, Schalm SW, Hadziannis S, Sanchez-Tapias J, Almasio P (1995) Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 21: 77-82
28. Balanzo J, Such J, Sainz S (1990) Long term survival and severe rebleeding after variceal sclerotherapy. Surg Gynecol Obstet 6: 489-492
29. Casttera I, Hartmann DJ, Chapel C, Guettier C, Mall F, Lons T (2000) Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J Hepatol 32: 412-418
30. Zuner CA, Apsner RC, Kranz A, Kramer L, Madl C, Schneider B (1996) Outcome prediction for patients with cirrhosis of the liver in a medical ICU: a comparison of the APACHE scores and liver specific scoring systems. Intensive Care Med 1996 22: 559-563
31. Babbs C, Hunt L, Haboubi N, Smith A, Rowan BP, Warens TW (1988) Type III procollagen peptide: a marker of disease activity and prognosis in primary biliary cirrhosis. Lancet i: 1021-1024
32. Jansen P (1990) Life expectancy in liver cirrhosis after the first variceal hemorhage: whose survival can be improved. Scand J Gastroenterol 178P [Suppl]: 196-210
33. Rivard CI, Esnaola S, Villeneuve JP (1.987) Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 7: 660-664